Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan

Pourjamal, NegarLe Joncour, VadimVereb, GyörgyHonkamaki, CillaIsola, JormaLeyton, Jeffrey V.Laakkonen, PirjoJoensuu, HeikkiBarok, Márk2025-03-072025-03-072025Translational Oncology. -53 (2025), p. 1-9. -(cikkazonosító)102284. -Translational Oncology. - 1936-52331936-5233https://hdl.handle.net/2437/388043Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecanfolyóiratcikkopen acces articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM128481OrvostudományokElméleti orvostudományokhttps://linkinghub.elsevier.com/retrieve/pii/S1936523325000154szerzőhttp://dx.doi.org/10.1016/j.tranon.2025.1022842025-03-0700140516440000185215417000